Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779524 | 0.81 | XDH (0.33) | HPGDXDHARALDH1A1HSD17B10 | |
| SCHEMBL19768957 | 0.78 | XDH (0.32) | XDHAR | |
| SCHEMBL19879506 | 0.78 | NAMPT (0.34) | HPGDXDHAR | |
| SCHEMBL23492895 | 0.77 | NR3C1 (0.31) | HPGDXDH | |
| SCHEMBL23492897 | 0.75 | XDH (0.30) | XDH | |
| SCHEMBL21884012 | 0.75 | TSHR (0.38) | HPGDXDHARALDH1A1TSHR | |
| SCHEMBL19880391 | 0.70 | GABRA1 (0.33) | SLC22A12ARALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL29940793 | 0.70 | XDH (0.51) | HPGDXDHSLC22A12ARALDH1A1 | |
| SCHEMBL28867665 | 0.70 | XDH (0.51) | HPGDXDHSLC22A12ARALDH1A1 | |
| SCHEMBL21547599 | 0.68 | PTGS2 (0.46) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | MGLL 1153/4885HPGD 1517/4885XDH 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.